{"id":"abiraterone-acetate-tablets","safety":{"commonSideEffects":[{"rate":"27%","effect":"Fatigue"},{"rate":"21%","effect":"Hypertension"},{"rate":"20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL271227","moleculeType":"Small molecule","molecularWeight":"391.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, leading to a decrease in testosterone levels in the body.","oneSentence":"CYP17 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:19.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT04662580","phase":"PHASE1","title":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-03","conditions":"Metastatic Prostate Cancer","enrollment":183},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT04221542","phase":"PHASE1","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2020-03-04","conditions":"Prostate Cancer","enrollment":479},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT01314118","phase":"PHASE2","title":"IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2011-05-04","conditions":"Prostate Cancer, Prostatic Neoplasm","enrollment":131},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT07311694","phase":"PHASE3","title":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-02","conditions":"PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer","enrollment":370},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT06568094","phase":"PHASE1, PHASE2","title":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-09-25","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT01961843","phase":"NA","title":"Abiraterone Acetate for Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01-14","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT05276492","phase":"PHASE1","title":"Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-01-24","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm","enrollment":50},{"nctId":"NCT06527690","phase":"PHASE2","title":"Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Latin American Cooperative Oncology Group","startDate":"2025-04-30","conditions":"Prostate Cancer, Castrate Resistant Prostate Cancer, Homologous Recombination Deficiency","enrollment":""},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT05588609","phase":"PHASE2","title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","status":"TERMINATED","sponsor":"Merus B.V.","startDate":"2022-11-17","conditions":"NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer","enrollment":13},{"nctId":"NCT06689163","phase":"PHASE1, PHASE2","title":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-12-11","conditions":"Prostate Cancer","enrollment":66},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT03348670","phase":"PHASE2, PHASE3","title":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2023-08-18","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT05413421","phase":"PHASE1","title":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"ORIC Pharmaceuticals","startDate":"2022-06-01","conditions":"Metastatic Prostate Cancer","enrollment":250},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT07104617","phase":"PHASE1, PHASE2","title":"Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）","status":"NOT_YET_RECRUITING","sponsor":"TYK Medicines, Inc","startDate":"2025-08","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":48},{"nctId":"NCT05401214","phase":"","title":"Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT07001709","phase":"PHASE4","title":"Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)","status":"RECRUITING","sponsor":"Deventer Ziekenhuis","startDate":"2024-04-12","conditions":"Prostate Cancer, Pain Cancer","enrollment":29},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT06971211","phase":"PHASE2","title":"Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC","status":"RECRUITING","sponsor":"Jianbin Bi","startDate":"2024-11-27","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":40},{"nctId":"NCT02025010","phase":"PHASE2","title":"Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-01-27","conditions":"Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT04556617","phase":"PHASE1, PHASE2","title":"PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Opna Bio LLC","startDate":"2020-09-21","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":19},{"nctId":"NCT06652607","phase":"","title":"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-12-20","conditions":"Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer","enrollment":152},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT00887198","phase":"PHASE3","title":"Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-04-28","conditions":"Prostate Cancer","enrollment":1088},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT02405858","phase":"PHASE4","title":"A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-04-10","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":51},{"nctId":"NCT02608359","phase":"","title":"A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer","status":"WITHDRAWN","sponsor":"Johnson & Johnson Private Limited","startDate":"2016-05-31","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":93},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496},{"nctId":"NCT04812366","phase":"PHASE2","title":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-09-21","conditions":"Prostate Cancer","enrollment":315},{"nctId":"NCT01650194","phase":"PHASE2","title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT06329830","phase":"PHASE1, PHASE2","title":"177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2024-10","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT06500247","phase":"PHASE2","title":"Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-07-31","conditions":"The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT06473259","phase":"","title":"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients","status":"RECRUITING","sponsor":"Santa Chiara Hospital","startDate":"2016-12-16","conditions":"Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Tumor","enrollment":3000},{"nctId":"NCT04458311","phase":"PHASE1, PHASE2","title":"Abiraterone Acetate in Combination With Tildrakizumab","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":13},{"nctId":"NCT02543255","phase":"PHASE2","title":"Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-09","conditions":"Prostate Cancer","enrollment":76},{"nctId":"NCT04887506","phase":"PHASE3","title":"TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Tavanta Therapeutics","startDate":"2021-05-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer","enrollment":107},{"nctId":"NCT06193993","phase":"PHASE1","title":"Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2021-11-30","conditions":"Prostate Cancer, Metastatic Cancer, Hormone Sensitive Prostate Cancer","enrollment":10},{"nctId":"NCT05405439","phase":"PHASE1, PHASE2","title":"To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-08-25","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":39},{"nctId":"NCT06099990","phase":"PHASE1","title":"Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10","conditions":"High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":660},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT01995513","phase":"PHASE4","title":"Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-22","conditions":"Prostate Cancer","enrollment":509},{"nctId":"NCT04628988","phase":"PHASE1","title":"A Study of CC-90011 and Comparators in Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-07-28","conditions":"Prostatic Neoplasms","enrollment":6},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT02160353","phase":"PHASE2","title":"Neo-adjuvant Abiraterone Prostate Study","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2015-07-09","conditions":"High Risk Localised Prostate Carcinoma","enrollment":45},{"nctId":"NCT05376722","phase":"PHASE2","title":"A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer","status":"UNKNOWN","sponsor":"Hongqian Guo","startDate":"2022-02-22","conditions":"Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT05167175","phase":"PHASE2","title":"The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation","status":"UNKNOWN","sponsor":"Hongqian Guo","startDate":"2022-03-01","conditions":"Prostate Cancer, Prostate Carcinoma, Metastatic Prostate Cancer","enrollment":30},{"nctId":"NCT01717053","phase":"PHASE2","title":"Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2014-01-17","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT05406999","phase":"PHASE2","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-02-01","conditions":"Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer","enrollment":900},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT05422911","phase":"PHASE2","title":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2022-06-30","conditions":"Metastatic Cancer, Neoplasm, Prostate","enrollment":200},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT01517802","phase":"PHASE3","title":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-03-28","conditions":"Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer","enrollment":32},{"nctId":"NCT02268175","phase":"PHASE2","title":"Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":"Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer","enrollment":75},{"nctId":"NCT04862091","phase":"PHASE2","title":"Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-23","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":69},{"nctId":"NCT03551782","phase":"PHASE1","title":"A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-06-28","conditions":"Castration-Resistant Prostatic Neoplasms","enrollment":33},{"nctId":"NCT04735913","phase":"EARLY_PHASE1","title":"Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2020-05-05","conditions":"Abiraterone Acetate, Gene Polymorphism, Pharmacokinetic","enrollment":81},{"nctId":"NCT02737332","phase":"PHASE2","title":"A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-03-21","conditions":"Prostate Cancer","enrollment":53},{"nctId":"NCT01751451","phase":"PHASE2","title":"3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12-18","conditions":"Prostate Cancer","enrollment":124},{"nctId":"NCT04296578","phase":"PHASE1","title":"Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2020-10","conditions":"Prostate Cancer, Castrate Resistant Prostate Cancer","enrollment":""},{"nctId":"NCT04889651","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-04-15","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT02867020","phase":"PHASE2","title":"Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels","status":"COMPLETED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2017-10-11","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT04863105","phase":"PHASE1","title":"Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2017-11-24","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT02867852","phase":"PHASE2","title":"Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2015-03","conditions":"Salivary Glands Tumors","enrollment":24},{"nctId":"NCT01842321","phase":"PHASE2","title":"Abiraterone Acetate in Molecular Apocrine Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2013-07","conditions":"Breast Cancer","enrollment":34},{"nctId":"NCT03093272","phase":"PHASE2","title":"A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-06-23","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT01591122","phase":"PHASE3","title":"Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-03-27","conditions":"Prostate Cancer","enrollment":313},{"nctId":"NCT02217566","phase":"PHASE2","title":"Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-23","conditions":"Prostatic Neoplasms","enrollment":46},{"nctId":"NCT02426333","phase":"","title":"Optimizing Abiraterone Therapy","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":56},{"nctId":"NCT04056754","phase":"PHASE3","title":"Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2014-07-16","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":268},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":"Prostatic Neoplasms","enrollment":68},{"nctId":"NCT01695135","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08-09","conditions":"Prostate Neoplasms","enrollment":214},{"nctId":"NCT01867710","phase":"PHASE2","title":"Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2013-07-16","conditions":"Prostate Cancer","enrollment":164},{"nctId":"NCT02379390","phase":"PHASE2","title":"Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-06-17","conditions":"Prostate Cancer Metastatic","enrollment":8},{"nctId":"NCT01381874","phase":"PHASE2","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-24","conditions":"Metastatic ER+ Her2- Breast Cancer, Postmenopausal","enrollment":297},{"nctId":"NCT01994590","phase":"PHASE2","title":"Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-19","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT01685983","phase":"PHASE2","title":"A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08-30","conditions":"Prostate Cancer","enrollment":82},{"nctId":"NCT01834209","phase":"","title":"A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Prostate Neoplasms","enrollment":""},{"nctId":"NCT01717898","phase":"PHASE1, PHASE2","title":"A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Charles Ryan","startDate":"2013-01-31","conditions":"Castrate-resistant Prostate Cancer","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZYTIGA®"],"phase":"phase_2","status":"active","brandName":"Abiraterone acetate tablets","genericName":"Abiraterone acetate tablets","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abiraterone acetate tablets are a small molecule inhibitor that targets the cytochrome P450 17A1 enzyme, specifically inhibiting its steroid 17-alpha-hydroxylase/17,20 lyase activity. They are used to treat conditions such as high-risk localized prostate carcinoma and prostate cancer, as well as other conditions including healthy volunteers, according to ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}